FDA Investigator CDR Donald Ertel
CDR Donald Ertel has conducted inspections on 16 sites in 6 countries as of 18 Apr 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
16
Last Inspection Date:
18 Apr 2024
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
France,
United States of America,
Mexico,
Germany,
Ireland,
Denmark
FDA Investigators that have inspected at least one site in common with CDR Donald Ertel:
Alan L Truong,
Alexey Khrenov, PhD,
Alicia M Mozzachio,
Amy Hsu, PhD,
Andrew "Drew" Haack, PhD,
Andrew K Haack, PhD,
Anita Narula, PhD,
Anita R Michael,
Ann Marie Montemurro,
Ann Marie Schofield,
Arie C Menachem,
Azza Talaat,
Barbara Janine Breithaupt,
Barbara M Frazier,
Bijoy Panicker,
Bradley Dworak, PhD,
Brentley S Collins,
Brian M Janelsins, PhD,
Bruce D Meade,
Burnell M Henry,
CDR Cecily Jones,
Charles Yuanchia Kuo, PhD,
Chava Kimchi Sarfaty, PhD,
Christian D Lynch (CDL),
Christine A Harman, PhD,
Christopher R Czajka,
Colleen F Hoyt,
Craig D Zagata,
Cynthia Jim, CSO,
Cynthia L Kelley,
Daniel C Kearns,
David E Bailey,
Deborah M Trout,
Destry M Sillivan,
Devaughn Edwards,
Dino A Fiegelstock,
Donna D Gallien, MPH,
Dr. Gang Wang, PhD,
Dr. Willie F Vann, PhD,
Edmund F Mrak, Jr,
Eliezar Ramos,
Gene D Arcy,
Graeme E Price,
Graeme Price,
Hailin Wang (Sheena), PhD,
Helen B Ricalde,
Hoda N Abadeer,
Holly Brevig,
J David Doleski,
Jacqueline Mdiaz Albertini,
Jakob Reiser, PhD,
James E Keller, PhD,
James M Mason,
James R Evans,
Jean Lhu Primmer,
Jennifer L Bridgewater,
Jennifer L Schmidt,
Jeremy W Rotton,
Jessica Chery,
Joan A Loreng,
Joan Johnson,
John F Cipollo,
John M Mcinnis,
José E Meléndez,
Joseph George,
Joshua J Silvestri,
Julie D Bringger,
Justin A Boyd,
Kathryn E King,
Kelly R Lewis,
Kevin P Foley,
Kristy A Zielny,
Kula N Jha,
Laressa R Gray,
Laura Fontan, MS,
Laurel A Beer,
Lauren M Lilly, PhD,
Laurie P Norwood,
LCDR Debra Emerson,
Linda Thai,
Lisa K Capron,
Lisa P Oakes,
Lori Peters,
Lydia S Chan,
Madushini Dharmasena, PhD,
Marion Michaelis,
Mariza M Jafary,
Marsha W Major,
Meisha R Sampson,
Meisha Waters,
Melanie L Drayton,
Michael C Kennedy, PhD,
Michael Havert, PhD,
Michael S Araneta,
Michael Shanks, MS,
Michele L Forster, PhD,
Michele L Obert,
Mihaly S Ligmond,
Mikhail V Ovanesov, PhD,
Mra Davism,
Myra K Casey,
Nancy T Waites,
Nataniel Phillips Sylvain, PhD,
Nicole K Trudel,
Nikisha M Bolden,
Omotunde O Osunsanmi,
Patrick C Klotzbuecher,
Patsy J Domingo,
Paula A Trost,
Phillip C Thai,
Prabhu P Raju,
Prajakta A Varadkar,
Rabia Ballica, PhD,
Ralph A Erickson,
Ramon E Martinez,
Rebecca K Olin,
Reyes Candau Chacon, PhD,
Richard Heath Coats,
Richard Ledwidge (nmi), PhD,
Richard W Thornton,
Riley C Myers, PhD,
Robert C Coleman,
Robert Jennings,
Robert Sausville,
Robert W Fisher,
Rose Ashley,
S Lori Brown, PhD MPH,
Sarah B Tanksley,
Scott E Norris,
Scott T Ballard,
Sharon K Thoma, PharmD,
Sidney B Priesmeyer,
Simone E Pitts,
Solomon Yimam (SY),
Steven B Hertz,
Steven C Derrick,
Steven E Bowen, PhD,
Steven Fong, MS, PhD,
Susan F Laska, MS,
Susan M Jackson,
Teegan Dellibovi Ragheb, PhD,
Thuy T Nguyen, LCDR,
Tina S Roecklein,
Unnee Ranjan,
V Teres Speer,
Vanessa Y Gelsey, PhD,
Vanessa Y Jacobs,
Wayne E Seifert,
Wei Wang, PhD,
William D Tingley,
Xu Michael Di, PhD,
Yideng Liang,
Yonggang Wang, PhD,
Yuan Chia Kuo,
Yumi J Hiramine,
Zhaohui Ye,
Zhenzhen Liu, PhD,
Zhong Li, PhD,
Zhongren Wu
CDR Donald Ertel's Documents
Publish Date | Document Type | Title |
---|---|---|
June, 2017 | FDA 483 | SAFC Carlsbad Inc. - Form 483, 2017-06-22 |
October, 2015 | EIR | AGC Biologics A/S - EIR, 2015-10-13 |
June, 2017 | FDA 483 | KITE PHARMA, INC. - Form 483, 2017-06-16 |
August, 2018 | FDA 483 | Laboratorios Silanes, S.A. de C.V. - Form 483, 2018-08-03 |
June, 2017 | EIR | KITE PHARMA, INC. - EIR, 2017-10-18 |
April, 2016 | FDA 483 | AGC Biologics, Inc. - Form 483, 2016-04-22 |
June, 2011 | FDA 483 | Instituto Bioclon S.A. de C.V. - Form 483, 2011-06-22 |
June, 2017 | FDA 483 Response | KITE PHARMA, INC. - Form 483R, 2017-06-29 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more